Menu Search
Equities

HLS Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
74D:FRA

HLS Therapeutics Inc

Actions
  • Price (EUR)2.58
  • Today's Change0.02 / 0.78%
  • Shares traded--
  • 1 Year change-3.01%
  • Beta0.8959
Data delayed at least 15 minutes, as of Feb 16 2026 07:12 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.

  • Revenue in CAD (TTM)76.05m
  • Net income in CAD-19.22m
  • Incorporated2018
  • Employees85.00
  • Location
    HLS Therapeutics Inc10 Carlson Court, Suite 701ETOBICOKE M9W 6L2CanadaCAN
  • Phone+1 (647) 495-9000
  • Fax+1 (647) 495-9000
  • Websitehttps://www.hlstherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.